title: Risk strata-based therapy and outcome in stage Ib-IIa carcinoma cervix: single-centre ten-year experience.
abstract: OBJECTIVE
  To review the outcome of stage (Ib, IIa), cervical cancer patients were primarily treated with radical hysterectomy and risk-based postoperative therapy.
  
  
  METHODS
  Between January 2001 and December 2011, 601 cases underwent surgery followed by tailored therapy. Patients were classified into low risk (pelvic lymph node negative, tumour less than 4 cm, no evidence of lympho-vascular invasion, less than one-third of thickness of surgical stoma involved), intermediate risk (positive lympho-vascular space invasion, tumour size more than 4 cm, and deep invasion of cervical stroma), and high risk (pelvic lymph node involved, positive parametrial, or vaginal margins) groups. Postoperative adju-vant therapy in the form of radiotherapy alone to those with intermediate risk and chemo-radiotherapy to those with high risk was given to patients. The median follow-up was 60 months.
  
  
  RESULTS
  The majority of patients had intermediate risk. The overall event-free survival (EFS) at five years was 74.37%, with EFS of 86.5% in those from the low-risk group, 73% in those from the intermediate-risk group, and 64% in those from the high-risk group. In conclusion, risk strata-based adjuvant postoperative therapy is able to provide a favourable outcome in patients with stage Ib-IIa cervical cancer with a nearly 11% improvement in survival compared with historical control.
authors: Department of Gynaec-oncology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka 560029, India.
authors: Rajshekar S
authors: RS
authors: Kundargi
authors: B
authors: B
authors: Guruprasad
authors: Praveen Shankar
authors: PS
authors: Rathod
authors: Pn
authors: P
authors: Shakuntala
authors: K
authors: K
authors: Shobha
authors: Vr
authors: V
authors: Pallavi
authors: K
authors: K
authors: Uma Devi
authors: Ud
authors: U
authors: Bafna
keywords: carcinoma cervix Ib–IIa; chemotherapy; radiotherapy
references: Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1501-7
references: 16750323
references: Gynecol Oncol. 1997 Jul;66(1):31-5
references: 9234917
references: J Clin Oncol. 2000 Apr;18(8):1606-13
references: 10764420
references: Cancer. 2000 May 15;88(10):2267-74
references: 10820348
references: Lancet. 1997 Aug 23;350(9077):535-40
references: 9284774
references: Gynecol Oncol. 1999 May;73(2):177-83
references: 10329031
references: Gynecol Obstet Fertil. 2004 Feb;32(2):116-21
references: 15123133
references: Gynecol Oncol. 1990 Sep;38(3):352-7
references: 2227547
references: Cancer. 1984 Dec 15;54(12):3035-42
references: 6498777
references: Chang Gung Med J. 2004 Oct;27(10):711-7
references: 15646293
references: Br J Cancer. 1995 Jun;71(6):1348-52
references: 7779737
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Obstet Gynecol. 1991 Jun;77(6):912-7
references: 2030867
references: Gynecol Oncol. 1988 Jul;30(3):381-7
references: 3391421
references: Gynecol Oncol. 2004 Aug;94(2):249-55
references: 15297159
references: Gynecol Oncol. 1991 Nov;43(2):108-12
references: 1743550
references: Gynecol Oncol. 1998 Mar;68(3):220-5
references: 9570969